2025 年 9 月 30 日 2022 年 5 月 31 日，辽宁成大股份有限公司（以下简称"公司"）2021 年年 度股东大会审议通过了《关于注册短期融资券发行额度的议案》，公司向中国银 行间市场交易商协会申请注册金额不超过 20 亿元（含）人民币的短期融资券发 行额度。公司于 2024 年 9 月 26 日完成了 2024 年度第三期短期融资券的发行， 金额为人民币 7 亿元，期限为一年，票面利率为 2.9%，票面价格 100 元/百元面 值。 2024 年度第三期短期融资券已于 2025 年 9 月 27 日到期，公司已完成该期 短期融资券本息的兑付。 特此公告。 辽宁成大股份有限公司 关于 2024 年度第三期短期融资券到期兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司董事会 证券代码：600739 证券简称：辽宁成大 公告编号：2025-074 ...

Market Overview - The biopharmaceutical sector increased by 0.78% on September 29, with Norseland leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Top Gainers in Biopharmaceutical Sector - Norseland (Code: 430047) closed at 24.80, up 6.57% with a trading volume of 68,400 shares and a transaction value of 169 million yuan [1] - Liaoning Chengda (Code: 600739) closed at 12.54, up 4.85% with a trading volume of 311,400 shares and a transaction value of 384 million yuan [1] - Rongchang Biotech (Code: 688331) closed at 110.00, up 4.76% with a trading volume of 83,500 shares and a transaction value of 900 million yuan [1] Top Losers in Biopharmaceutical Sector - Kanghua Biotech (Code: 300841) closed at 75.47, down 2.34% with a trading volume of 40,800 shares and a transaction value of 307 million yuan [2] - Baipusais (Code: 301080) closed at 58.51, down 2.32% with a trading volume of 20,000 shares and a transaction value of 117 million yuan [2] - Rili Pharmaceutical (Code: 603087) closed at 76.37, down 2.18% with a trading volume of 120,740 shares and a transaction value of 1.573 billion yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 154 million yuan from institutional investors, while retail investors saw a net inflow of 1.47 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - Liaoning Chengda saw a net outflow of 52.59 million yuan from institutional investors, while retail investors had a net outflow of 40.07 million yuan [3] - Kanghua Biotech had a net inflow of 26.12 million yuan from institutional investors, but a net outflow of 47.70 million yuan from retail investors [3] - Three Life National Health (Code: 688336) had a net inflow of 23.37 million yuan from institutional investors, with retail investors also experiencing a net outflow [3]

Core Points - The company has successfully issued a short-term financing bond with a total amount of 800 million RMB [1] - The registered amount for short-term financing bonds is 3 billion RMB, valid for two years [1] - The funds raised will primarily be used to repay interest-bearing debts [1] Summary by Sections - **Issuance Details** - The company issued 800 million RMB of short-term financing bonds on September 23, 2025 [1] - The funds were fully received on September 24, 2025 [1] - **Approval and Registration** - The issuance was approved during the company's second extraordinary general meeting on October 23, 2024 [1] - The China Interbank Market Dealers Association issued a registration acceptance notice for the bond [1] - **Underwriting** - Dalian Bank Co., Ltd. acted as the lead underwriter for the bond issuance [1]

Core Points - Liaoning Chengda announced the approval of a short-term financing bond issuance limit of 3 billion yuan [2] - The registration notice for the bond issuance has been accepted by the China Interbank Market Dealers Association, valid for 2 years [2] - The company successfully issued 800 million yuan of short-term financing bonds on September 23, 2025, with funds fully received on September 24, 2025, primarily for repaying interest-bearing debts [2]

证券代码：600739 证券简称：辽宁成大 公告编号：2025－073 辽宁成大股份有限公司 2025 年度第二期短期融资券发行结果公告 公 司 本 次 短 期 融 资 券 发 行 相 关 文 件 详 见 上 海 清 算 所 网 站 （http://www.shclearing.com/）。 特此公告。 辽宁成大股份有限公司董事会 2025 年 9 月 26 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 10 月 23 日，辽宁成大股份有限公司（以下简称"公司"）2024 年第二次 临时股东会审议通过了《关于注册短期融资券发行额度的议案》。中国银行间市场交 易商协会已签发《接受注册通知书》（中市协注[2025]CP68 号），接受公司短期融资券 注册，注册金额为 30 亿元，注册额度自该通知书落款之日起 2 年内有效，由大连银 行股份有限公司主承销。 公司于 2025 年 9 月 23 日在全国银行间市场发行规模为 8 亿元人民币的辽宁成大 股份有限公司 2025 年度第二期短期融资券，募集资金已于 2 ...

Core Points - The company received a no-objection letter from the Shenzhen Stock Exchange regarding the non-public issuance of exchangeable bonds by its major shareholder, Liaoning Chengda Co., Ltd. [1] - Liaoning Chengda plans to issue exchangeable bonds with a total face value of up to 2.8 billion RMB, which is confirmed to meet the listing conditions of the Shenzhen Stock Exchange [1] - The no-objection letter is valid for 12 months from the date of issuance [1] Shareholding Structure - As of the announcement date, Liaoning Chengda and its concerted parties hold a total of 1,366,927,688 shares of the company, accounting for 17.97% of the total share capital [2] - The issuance of the exchangeable bonds will not lead to significant changes in the company's equity structure [2] - The company will disclose further developments regarding the non-public issuance of exchangeable bonds in accordance with regulatory requirements [2]

Core Viewpoint - Liaoning Chengda Co., Ltd. has received a no-objection letter from the Shenzhen Stock Exchange regarding its non-public issuance of exchangeable bonds, confirming that the issuance meets the listing conditions [1] Group 1: Stock Performance - As of September 18, 2025, Liaoning Chengda's stock closed at 11.97 yuan, down 2.84% from the previous trading day, with a total market capitalization of 18.311 billion yuan [1] - The stock opened at 12.31 yuan, reached a high of 12.31 yuan, and a low of 11.88 yuan, with a trading volume of 213 million yuan and a turnover rate of 1.15% [1] Group 2: Bond Issuance - The company plans to issue exchangeable bonds with a reduced scale of no more than 2.8 billion yuan, down from the previously approved 5 billion yuan [1] - The no-objection letter confirms that the application for the issuance of exchangeable bonds with a face value of up to 2.8 billion yuan is compliant with the listing conditions [1] - The company must submit the application for listing transfer within twelve months from the issuance of the no-objection letter, or it will automatically expire [1]

Group 1 - The core point of the announcement is that Liaoning Chengda's controlling shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., holds 247,772,048 shares, accounting for 16.20% of the total share capital as of September 17, 2025 [2] - Shaoguan Gaoteng has released a pledge of 6,150,000 shares, while the remaining pledged shares amount to 104,070,000 shares [2] - The remaining pledged shares represent 42.00% of the shares held by Shaoguan Gaoteng and 6.80% of the total share capital of the company [2]

证券代码：600739 证券简称：辽宁成大 公告编号：2025-070 辽宁成大股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 9 月 30 日 前 访 问 网 址 https://eseb.cn/1rsf6BRPPO0 或使用微信扫描小程序码进行会前提问，公司将 在说明会上对投资者普遍关注的问题进行回答。 辽宁成大股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日披露公 司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度 经营成果、财务状况，公司计划于 2025 年 9 月 30 日 13:00-14:00 举行 2025 年 半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 | 董事长 | 徐 | 飚先生 | | --- | --- | --- | | 董事、总裁 | | 张善伟先生 | | 独立董事 | | 余鹏翼先生 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025-072 辽宁成大股份有限公司 关于股东股份解质押的公告 | | | 本次解质押股份如后续用于质押，公司将按照相关法律法规履行信息披露义 务。 特此公告。 辽宁成大股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至 2025 年 9 月 17 日，辽宁成大股份有限公司（以下简称"公司"） 控股股东韶关市高腾企业管理有限公司（以下简称"韶关高腾"）持有公司股份 247,772,048 股，占公司总股本比例为 16.20%。韶关高腾本次解质押股份数量为 6,150,000 股，剩余被质押股份数量为 104,070,000 股，剩余被质押股份占其所 持有公司股份比例为 42.00%，占公司总股本比例为 6.80%。 公司于 2025 年 9 月 17 日接到韶关高腾函告，获悉其所持有的公司部分股份 被解除质押，具体事宜如下。 | 股东名称 | 韶关市高腾企业管理有限公司 | | --- | --- | | 本次解除质押股份 | 6,1 ...